Chimeric antigen receptor (CAR) T-cell therapy is a successful novel cell-based therapy in hemato-oncology, and it might also be a promising therapeutic option for TP53-mutant AML/MDS. The gene discussed is TP53; the disease is myelodysplastic syndrome.